Patents by Inventor Andrea Rachel LEUBITZ

Andrea Rachel LEUBITZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11191848
    Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: December 7, 2021
    Assignee: Vascular Biogenics Ltd.
    Inventors: Andrea Rachel Leubitz, Naamit Sher, Erez Feige, Eyal Breitbart
  • Publication number: 20200046852
    Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
    Type: Application
    Filed: July 8, 2019
    Publication date: February 13, 2020
    Applicant: Vascular Biogenics Ltd.
    Inventors: Andrea Rachel LEUBITZ, Naamit SHER, Erez FEIGE, Eyal BREITBART
  • Patent number: 10383954
    Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: August 20, 2019
    Assignee: Vascular Biogenics Ltd.
    Inventors: Andrea Rachel Leubitz, Naamit Sher, Erez Feige, Eyal Breitbart
  • Publication number: 20170354746
    Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
    Type: Application
    Filed: May 26, 2017
    Publication date: December 14, 2017
    Applicant: Vascular Biogenics Ltd.
    Inventors: Andrea Rachel LEUBITZ, Naamit Sher, Erez Feige, Eyal Breitbart
  • Patent number: 9682154
    Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: June 20, 2017
    Assignee: Vascular Biogenics Ltd.
    Inventors: Andrea Rachel Leubitz, Naamit Sher, Erez Feige, Eyal Breitbart
  • Publication number: 20160121001
    Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
    Type: Application
    Filed: February 4, 2014
    Publication date: May 5, 2016
    Applicant: Vascular Biogenics Ltd.
    Inventors: Andrea Rachel LEUBITZ, Naamit SHER, Erez FEIGE, Eyal BREITBART